Q1 EPS Forecast for Lexaria Bioscience Raised by Analyst

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Analysts at HC Wainwright lifted their Q1 2025 earnings estimates for Lexaria Bioscience in a research report issued to clients and investors on Monday, November 25th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.08) per share for the quarter, up from their previous estimate of ($0.09). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Lexaria Bioscience’s Q2 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($8.00) EPS and FY2025 earnings at ($0.31) EPS.

Lexaria Bioscience Trading Down 1.9 %

LEXX opened at $2.09 on Wednesday. The company’s fifty day moving average price is $2.67 and its two-hundred day moving average price is $3.00. The company has a market cap of $33.06 million, a price-to-earnings ratio of -4.82 and a beta of 1.02. Lexaria Bioscience has a 1-year low of $1.20 and a 1-year high of $6.85.

Institutional Trading of Lexaria Bioscience

Several institutional investors and hedge funds have recently made changes to their positions in LEXX. HighTower Advisors LLC purchased a new stake in Lexaria Bioscience during the third quarter worth about $40,000. XTX Topco Ltd boosted its position in shares of Lexaria Bioscience by 47.8% in the third quarter. XTX Topco Ltd now owns 18,626 shares of the company’s stock valued at $57,000 after acquiring an additional 6,024 shares during the period. Renaissance Technologies LLC bought a new position in shares of Lexaria Bioscience in the second quarter valued at approximately $63,000. Geode Capital Management LLC boosted its position in shares of Lexaria Bioscience by 31.0% in the third quarter. Geode Capital Management LLC now owns 150,391 shares of the company’s stock valued at $459,000 after acquiring an additional 35,608 shares during the period. Finally, Armistice Capital LLC bought a new position in shares of Lexaria Bioscience in the second quarter valued at approximately $2,836,000. Hedge funds and other institutional investors own 13.06% of the company’s stock.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.